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Background: Non-traditional CD4+CD25–CD69+ T cells were found to be involved in disease progression in
tumor-bearing mouse models and cancer patients recently. We attempted to define whether this subset of T cells
were related to leukemia relapse after allogeneic hematopoietic cell transplantation (allo-HSCT).
Methods: The frequency of CD4+CD25–CD69+ T cells among the CD4+ T cell population from the bone marrow
of relapsed patients, patients with positive minimal residual disease (MRD+) and healthy donors was examined by
flow cytometry. The CD4+CD25-CD69+ T cells were also stained with the intracellular markers to determine the
cytokine (TGF-β, IL-2 and IL-10) secretion.
Results: The results showed that the frequency of CD4+CD25–CD69 + T cells was markedly increased in patients in
the relapsed group and the MRD + group compared to the healthy donor group. The percentage of this subset of
T cells was significantly decreased after effective intervention treatment. We also analyzed the reconstitution of
CD4+CD25–CD69+ T cells at various time points after allo-HSCT, and the results showed that this subset of T cells
reconstituted rapidly and reached a relatively higher level at +60 d in patients compared to controls. The incidence
of either MRD+ or relapse in patients with a high frequency of CD4+CD25-CD69+ T cells (>7%) was significantly
higher than that of patients with a low frequency of CD4+CD25-CD69+ T cells at +60 d, +90 d and +270 d after
transplant. However, our preliminary data indicated that CD4+CD25-CD69+ T cells may not exert immunoregulatory
function via cytokine secretion.
Conclusions: This study provides the first clinical evidence of a correlation between non-traditional CD4+CD25-CD69+
Tregs and leukemia relapse after allo-HSCT and suggests that exploration of new methods of adoptive immunotherapy
may be beneficial. Further research related to regulatory mechanism behind this phenomenon would be necessary.
Keywords: Regulatory T cells, Allogeneic Hematopoietic Stem Cell Transplantation, Relapse, Leukemia, Immunoregulatory* Correspondence: huangxiaojun@bjmu.edu.cn
†Equal contributors
1Peking University People’s Hospital, Peking University Institute of
Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell
Transplantation, Beijing 100044, China
2Peking-Tsinghua Center for Life Sciences, Beijing 100871, China
© 2014 Zhao et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Zhao et al. Journal of Translational Medicine 2014, 12:187 Page 2 of 10
http://www.translational-medicine.com/content/12/1/187Introduction
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is a potentially curative procedure for patients with
hematological malignancies, although leukemia relapse re-
mains one of the most common causes of treatment failure
after transplant. However, the precise biological mechanism
responsible for relapse remains unclear. Allo-HSCT can
also be considered a type of immunotherapy directed to-
ward malignant hematologic diseases or the graft-versus-
leukemia (GVL) effect due to either infused immunocytes
in the graft or reconstituted T cells after transplant. Thus, it
would be beneficial to identify particular subsets of T cells
related to the GVL effect as well as graft-versus-host dis-
ease (GVHD). Furthermore, confirmation of any correlation
between clinical relapse and a specific subset of T cells, as
well as further elucidation of the mechanism behind this
phenomenon, would be beneficial for exploring new
methods of adoptive immunotherapy and preventive strat-
egies against post-transplant relapse.
There is mounting evidence suggesting that regulatory T
cells (Tregs) play an important role in maintaining immune
homeostasis and regulating negative immune responses
[1,2]. It has been shown that Tregs possess the capacity to
suppress T cell-mediated GVHD after allo-HSCT [3-7].
However, several studies have demonstrated that the pres-
ence of Tregs in either the tumor microenvironment or cir-
culation might be involved in immune escape mechanisms
and the failure of the host to trigger an efficient immuno-
logical antitumor response [8-10]. Currently, 3 major sub-
types of CD4+ Tregs have been recognized to negatively
regulate the immune response: CD4+CD25+Foxp3+ cells,
Tr1 cells and Th3 cells [11-13]. However, the ineffective-
ness of treatment towards CD4+CD25- Tregs in cancer
therapy indicates that there may be other mechanisms re-
sponsible for the ability of tumor cells to evade immuno-
logical attack. Recently, a new subset of CD4+ Tregs that
primarily express CD4 and CD69, but not CD25, has been
identified in a tumor-bearing mouse model [14]. Han et al.
demonstrated that this new type of Tregs could exert
immunosuppressive activity via cell-cell contact with
membrane-bound TGF-β1 in mice [14]. Another study
confirmed that an increase in the number of CD4+CD25-
CD69+ Tregs among both the peripheral blood and liver-
infiltrating lymphocytes of hepatocellular carcinoma (HCC)
patients were correlated with tumor size, vascular invasion
and disease stage [15].
Based on these reports, our colleagues demonstrated that
a high frequency and increased number of CD4+CD25-
CD69+ T cells in the peripheral blood were associated with
a reduced risk of acute GVHD. Additionally, a low per-
centage of this subset of T cells in allografts was shown
to predict an increased risk of acute GVHD [16]. These
data suggested immunomodulatory effects of these cells
and led us to investigate the possible functional roles ofCD4+CD25-CD69+ T cells in leukemia relapse after trans-
plantation. Until now, there have been no reports on the
immune regulatory action of this subset of Tregs in the
relapse of malignant hematological disease. Therefore, we
sought to assess the clinical correlation between the num-
ber of CD4+CD25-CD69+ T cells in donor bone marrow
and leukemia relapse after allo-HSCT, and we also per-
formed a preliminary exploration into the potential im-
mune mechanism responsible for this association.Methods
Patients
Twenty-nine patients with malignant hematological disease
who were treated with non-T-cell-depleted allo-HSCT
at the Peking University Institute of Hematology from
November 2009 to April 2011, including patients under-
going hematological relapse (n = 22) and those with detect-
able minimal residual disease (MRD, n = 7), were selected
as the initial subjects. The remaining 56 patients who re-
ceived allo-HSCT from October 2009 to July 2010 were
also enrolled in this study for the prospective cohort ana-
lysis. This study was approved by the ethics committee of
Peking University People’s Hospital. Written informed con-
sent was obtained from all patients prior to their entry into
the study in accordance with the Declaration of Helsinki.
The patient and transplant characteristics are summarized
in Additional file 1: Table S1 & Table 1.Transplant protocols
All of the patients in this study received myeloablative con-
ditioning regimens. Transplantations were performed as
previously described [17,18]. Patients who received human
leukocyte antigen (HLA)-matched related transplants were
treated with either the combination of busulfan (BU,
0.8 mg/kg iv, q6h) and cyclophosphamide (CTX, 1.8 g/m2/
d for 2 d) or total body irradiation (TBI, 7.7 Gy), given as 1
fraction, followed by CTX. Patients who received related
HLA-mismatched transplants were conditioned with either
BU +CTX+ human antithymocyte globulin (ATG, Sang
Stat, Lyon, France) (2.5 mg/kg/d iv for 4 d) or TBI +CTX+
ATG. All patients received G-CSF-mobilized bone marrow
(BM) and peripheral blood stem cell transfusion followed
by cyclosporine (CSA), mycophenolate mofetil (MMF)
and short-term methotrexate (MTX). CSA was started
on −9 d at a dosage of 2.5 mg/kg iv. The dosage of CSA
was adjusted to the blood concentration of 150–250 ng/ml
and was gradually reduced and eventually discontinued ap-
proximately 4 to 6 months after HSCT. MTX (15 mg/m2)
was administered by iv on +1 d; patients undergoing related
mismatched HSCT were treated with 10 mg/m2 MTX
on +3 d, +5 d and +11 d, whereas patients undergoing
related matched HSCT were treated with 10 mg/m2
MTX on +3 d and +6 d.




Patient age, median (range) age 31 (8–54)











High risk 29 (52.0%)
Standard risk 27 (48.0%)
Situation after allo-HSCT




AML, acute myeloid leukemia; B-ALL, B cell acute lymphoblastic leukemia;
CML, chronic myeloid leukemia; MDS, Myelodysplastic syndrome; BAL,
biphenotypic acute leukemia.
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Bone marrow from the initial 29 subjects was collected
either upon hematological relapse or the detection of
MRD. Among these patients, the bone marrow samples
of 19 patients who received interventions were also col-
lected. The number of days after the last stem cell infu-
sion is marked with a ‘+’. The MRD status of the 56
patients enrolled in the prospective cohort study was ex-
amined at the following time points: +30 d, +60 d, +90
d, +180 d, +270 d and +360 d. Bone marrow samples
from patients at the aforementioned time points were
also prospectively collected for MRD examination and
to determine the number of CD4+CD25-CD69+ cells by
flow cytometry (FCM).
Antibodies and FCM
Bone marrow samples were stained with anti-CD4 peri-
dinin chlorophyll protein (PerCP), anti-CD25 phyco-
erythrin (PE), anti-CD69 allophycocyanin (APC), anti-
CD122 PE and isotype-matched mouse antibodies (BD
Biosciences, Mountain View, CA, USA). Flow cytometry
was performed using a BD FACSSort machine (Becton
Dickinson Biosciences, San Jose, CA, USA). The fre-
quency of CD4+CD25-CD69+ T cells was calculated asthe percentage of positive cells in the CD4+ T cell frac-
tion and is shown as the median (range, 25th-75th per-
centiles). The data were analyzed using CellQuest
software (BD Biosciences).Definitions
Neutrophil recovery was defined as a neutrophil
count >0.5 × 109/l for 3 consecutive days, and platelet recov-
ery was defined as a platelet count >20 × 109/l without
transfusions for 7 consecutive days. Patients with malignan-
cies were categorized as ‘standard risk’ if they were either in
the first or second complete remission (CR1 or CR2) for
acute leukemia or in the chronic phase of chronic myeloid
leukemia (CML). Patients were classified as ‘high risk’ if
they were past the CR2 phase of acute leukemia, not in re-
mission, Philadelphia chromosome (Ph)-positive, beyond
the first chronic phase of CML or myelodysplastic syndrome
with refractory anemia with excess of blasts (MDS-RAEB).
Hematological relapse was defined as either the reappear-
ance of blasts in the peripheral blood or an unattained CR
following a course of standard antileukemia therapy, in
which BM was infiltrated with >5% but <20% blasts in a
representative smear. The positive MRD (MRD+) used in
this study was defined based on the detection of abnormal
expression of leukemia-specific genes such as BCR/ABL,
AML1/ETO, CBFβ/MYH11, E2A-PBX1 and WT1 and/or
leukemia-associated aberrant immune phenotypes (LAIPs).
Patients with specific leukemia fusion genes, including
AML1/ETO or CBFβ/MYH11, over one log rising, or with
other detectable fusion genes, including E2A-PBX1, MLL/
AF4 and TLS-ERG, were defined as MRD+. For those pa-
tients without leukemia-specific genes, detection of MRD
was performed as previously reported [19].Isolation and purification of CD4 + CD25-CD69+ T cells
Bone marrow mononuclear cells (BMNC) were isolated
from freshly obtained, heparinized bone marrow samples
(10 ml) by Ficoll-Hypaque density gradient (1.077 g/dl) cen-
trifugation at 1,500 rpm for 15 minutes. After washing
twice, the cells were resuspended in magnetic-activated cell
sorting (MACS) buffer (0.5% FBS, 2 mM EDTA in PBS,
pH= 7.2). First, CD4+ T cells were negatively selected using
the CD4+ T Cell Isolation Kit (Miltenyi Biotec, Auburn,
CA; Order no. 130096533) according to the manufacturer’s
protocol. The purity of each population was confirmed by
FCM to be >95%. Subsequently, the selected CD4+ T cells
were incubated with CD25 MicroBeads II (Miltenyi Biotec,
Auburn, CA; Order no. 130092983), and CD4+CD25- T
cells were isolated according to the manufacturer’s proto-
col. The purity of each population was confirmed by FCM
to be >90%. Finally, the CD69 MicroBead Kit II was used to
isolate CD69+ cells from the CD4+CD25- T cells. The iso-
lated cells were stained with anti-CD69 APC antibody to
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FCM analysis.
Cell surface phenotyping and intracellular staining by
flow cytometry
Anti-TGF-β PE, anti-IL-2 PE, anti-IL-10 PE, the other
fluorescent antibodies mentioned above and the respective
isotype controls were added to BMNCs at 1 × 106/l and in-
cubated for 30 min at 4°C in the dark. The cells were
washed once with ice-cold PBS (pH 7.2) containing 0.1%
NaN3 and 0.5% BSA and resuspended in 200 μl PBS. For
intracellular staining, the cells were fixed and permeabilized
for 30 min using the eBioscience Staining Intracellular An-
tigens for Flow Cytometry Kit (eBioscience, San Diego, CA,
USA). The cells were washed with permeabilization buffer
and labeled with cytokine-specific fluorescence-conjugated
anti-IL-2, anti-IL-10 or anti-TGF-β antibodies or the re-
spective isotype-matched Ig controls. The other BMNCs
were placed in Iscove’s modified Dulbecco’s medium
(IMDM) and incubated with phorbol myristate acetate
(PMA) (100 ng/ml) plus ionomycin (1.0 μg/ml, all reagents
from Sigma Chemical) for 5 h to stimulate maximum cyto-
kine production; Golgistop (0.7 μl/ml, BD Pharmingen) was
added to the samples during the last 4 h to trap the protein
in the cytoplasm.
Statistical analysis
Statistical analyses were performed using SPSS 18.0
(IBM Corporation, Armonk, NY, USA). The data were
summarized as median values (range, 25th-75th percen-
tiles). The Mann–Whitney U test was used for inde-
pendent sample comparisons between different groups.
For 2-related-sample comparisons of continuous vari-
ables, a 2-sided Wilcoxon rank-sum test was performed.
The Chi-square test was used for categorical variables.
All stated P-values are 2-sided, with P < 0.05 defined as
statistically significant.
Results
Higher frequency of CD4+CD25-CD69+ T cells in the bone
marrow of MRD + and relapsed patients
To investigate the relationship between CD4+CD25-
CD69+ T cells and leukemia relapse, we first examined
the frequency of these cells in the bone marrow from 29
patients who were treated for a malignant hematological
disease with allo-HSCT, including patients undergoing
hematological relapse (n = 22) and those with a positive
MRD status (n = 7). The bone marrow from 20 healthy
donors was used as the normal control. The frequency
of CD4+CD25-CD69+ T cells in the bone marrow from
the healthy donors was 2.79% (range, 2.11-4.94%);
however, the frequency of this subset was significantly
increased in patients with detectable MRD (7.60%,
range, 4.53-9.14%, P = 0.008) and those undergoinghematological relapse (12.96%, range, 8.62-20.49%, P <
0.001) compared to the control group. Additionally,
there was a significant difference in the percentage of
CD4+CD25-CD69+ T cells between the relapsed group
and MRD + group (P = 0.020, Figure 1a). CD69 and
CD25 expression on CD4+ T cells in the bone marrow
from a representative patient is shown in Figure 1b,
demonstrating that this set of T cells highly expresses
CD122, as previously reported [14].
Among these 29 patients, bone marrow samples from
19 patients after receiving intervention treatment [in-
cluding chemotherapy and/or donor lymphocyte infu-
sion (DLI, n = 16) or a second allo-HSCT (n = 3)] were
also collected to investigate the correlation of this subset
of T cells with treatment response. Eleven patients
achieved CR without any detectable MRD, and the other
8 patients either achieved partial remission (PR) or still
had detectable MRD. It was also observed that the fre-
quency of CD4+CD25-CD69+ T cells was decreased in
both sets of patients after the intervention [CR set,
8.24% (range, 7.53-9.44%) vs. 3.37% (range, 1.17-5.74%),
P = 0.011; PR/MRD + set, 17.90% (range, 8.52-25.78%) vs.
4.84% (range, 2.32-6.635%), P < 0.001, Figure 1c].
Dynamic monitoring of CD4+CD25-CD69 + T cells in the
bone marrow of patients after allo-HSCT
To investigate the dynamic reconstitution of CD4+CD25-
CD69+ T cells, the bone marrow from an additional 56 pa-
tients at +30 d, +60 d, +90 d, +180 d, +270 d and +360 d
after allo-HSCT was collected prospectively and analyzed
through FCM. The median follow-up was 628 d (range
107–900 d). The bone marrow samples from the first 3
time points (+30 d, +60 d and +90 d) were available from
all of the patients. The samples at +180 d were obtained
from 50 patients, the samples at +270 d were obtained from
44 patients, and the samples at +360 d were obtained from
41 patients. All 56 patients achieved hematopoietic recon-
stitution. During the follow-up, 7 patients (12.5%) experi-
enced hematological or extramedullary relapse at +90 d
(range +30-180 d), and 7 patients (12.5%) met the criteria
for positive MRD at +90 d (range +30-270 d). Among the
relapsed patients, only 1 patient with extramedullary re-
lapse acquired CR after treatment, and the others all died
of relapse. Among patients with detectable MRD, 5
achieved CR after intervention, and 2 patients died (one of
hematological relapse, the other of DLI-related severe
pneumonia). The detailed characteristics of the patients
with relapse indications are shown in Additional file 1:
Table S2. Forty-two patients did not undergo relapse or had
detectable MRD, and only 1 patient died of heart failure
during the follow-up period.
The percentage of CD4+CD25-CD69+ Tcells in the bone
marrow of 42 patients without any indication of relapse at
+30 d (1.49%, range, 0–3.99%), +60 d (4.40%, range, 2.24-
Figure 1 The frequency of CD4+CD25-CD69 + T cells in bone
marrow. (a) Scatter plot showing the frequency of CD4+CD25-CD69 + T
cells (median, range, 25th and 75th percentiles) in healthy donor (n = 20),
MRD+ patients (n = 7), relapsed patients (n = 22). (b) Representative dot
plot showing CD69 and CD25 expression on a gated population
of CD4+ T cells in a patient. The right figure shows the expression
of CD122 on CD4+CD25-CD69+ cells. (c) Pooled data showing a
comparison of the frequency of CD4+CD25–CD69+T cells
(median, range, 25th and 75th percentiles) before and after
intervention in patients with different treatment response.
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range, 3.53-10.30%), +270 d (4.58%, range, 1.87-6.58%)
and +360 d (6.13%, range, 3.14-11.7%) is shown in Figure 2.
Although there were no significant differences between
the frequency at +30 d, +60 d at +270 d compared to
the healthy controls (P = 0.390, P = 0.099 and P = 0.073,
respectively, Figure 2), it appeared that the frequencies
of CD4+CD25-CD69+ T cells at the other time points
were higher than those of the healthy controls, with
the exception of +30 d. The percentage of CD4+CD25-
CD69+ T cells in patients without any relapse indication
at +90 d, +180 d and +360 d was significantly higher than
that of the control group (P = 0.005, P= 0.01 and P= 0.004,
respectively). These results show that this subset of T cells
reconstituted rapidly and reached a relatively higher
level at +60 d in patients compared to controls.Figure 2 Dynamic monitoring of CD4+CD25-CD69 + T cells in
bone marrow of patients after allo-HSCT. Scatter plot showing
the percentage of CD4+CD25-CD69 + T cells in CD4+ T cells
(median, range, 25th and 75th percentiles) in bone marrow of
patients without any relapse indication. Compared to healthy donor,
**,P < 0.01, *,P < 0.05.
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CD4+CD25-CD69+ T cells at various time points
post-transplantation
We next compared the frequency of CD4+CD25-CD69+
T cells between groups of patients with (n = 14) and
without leukemia relapse or relapse indication (n = 42)
at each time point after transplantation. The percent-
ages of this subset of T cells in patients undergoing re-
lapse, with an indication for relapse, without any relapse
and without an indication for relapse are shown in
Table 2. Although there was a significant difference in
the frequency of CD4+CD25-CD69+ T cells from the
bone marrow at +60 d (P = 0.046; P > 0.05 at all other
time points, Table 2), it appeared that the frequencies of
this subset were slightly higher than those in patients
without leukemia relapse or any indication of relapse.
These 56 patients were then separated into 2 groups
at each time point according to the frequency of CD4+
CD25-CD69+ T cells. The cutoff value was defined at
7% because it was the upper limit of the CD4+CD25-
CD69+ T cell frequency in healthy controls. Patients
with a frequency less than 7% were defined as the low
CD4+CD25-CD69+ T cell group, whereas the remaining
patients were defined as the high CD4+CD25-CD69+ T
cell group. The incidence of either MRD + or relapse be-
tween these 2 groups was compared at each time point
after transplantation. The data in Table 3 show that the
incidence of either MRD + or relapse in the high CD4+
CD25-CD69+ T cell group was significantly greater
than that in the low CD4+CD25-CD69+ T cell group
at +60 d, +90 d and +270 d (P = 0.012, P = 0.027 and
P = 0.016, respectively). At other time points (+30 d, +180
d and +360 d), there were no significant differences
between these 2 groups (P > 0.05), but the ratio of pa-
tients with either positive MRD or relapse in the high-
level group also appeared to be slightly higher than
that of the low-level group (Table 4). Figure 3 shows
the dynamic change in the frequency of CD4+CD25-
CD69+ T cells in representative patients from the dif-
ferent groups (healthy donor, patients with MRD + and
relapsed patients).Table 2 The frequency of CD4+CD25-CD69+ T cells in patient
Time point Patients without leukemia







+360d 6.13 (3.14-11.7)CD4+CD25-CD69+ T cells may not display
immunoregulatory function via cytokine secretion
The results from the clinical analysis suggested that
these non-traditional CD4+CD25–CD69+ Tregs were
correlated with leukemia relapse after allo-HSCT. Thus,
we attempted to confirm the immunoregulatory roles of
CD4+CD25-CD69+ T cells in vitro. First, we attempted
to isolate this subset of T cell from bone marrow using
specific T cell isolation kits. However, due to the 3-marker
phenotype and low frequency of these cells, the use of 3
types of isolation (including CD4 negative selection, CD25
positive selection and CD69 positive selection) produced
too few target cells for the mixed leukocyte reactions
(data not shown). We then analyzed the secretion of
several important Th1/Th2 cytokines, including IL-2,
IL-10 and TGF-β, in this subset of T cells to investigate
whether they may be responsible for the proposed im-
munoregulatory function of this subset. The cytokine
secretion of CD4+CD25-CD69+ T cells in unstimu-
lated (PMA and ionomycin) bone marrow was ana-
lyzed in healthy donors (n = 6), patients without any
relapse indications (n = 5, termed as group A) and
MRD + patients or relapsed patients (MRD + patients,
n = 3; relapsed patients, n = 2; termed group B). As
shown in Figure 4a and in accordance with the results
described above, the frequency of CD4+CD25-CD69+ T
cells in group B was significantly higher than that in group
A (P = 0.028) and that in healthy donors (P = 0.006).
Despite the increased number of CD4+CD25-CD69+ T
cells that secreted TGF-β in unstimulated bone marrow
from group B compared to group A, this difference was
not statistically significant (P = 0.068 and P = 0.076, re-
spectively, Figure 4b), and no significant differences in
IL-2 and IL-10 secretion were observed among these 3
groups (P > 0.05, Figure 4b). Because CD69 is generally
considered an early activation marker of T cells, we then
examined whether the CD4+CD25-CD69+ T cells in
patients undergoing allo-HSCT constituted activated
T cells. The secretion of IL-2, IL-10 and TGF-β in
CD4+CD25-CD69+ T cells from the bone marrow after
PMA and ionomycin stimulation was analyzed in patientss with and without leukemia relapse or relapse indication
Patients with leukemia









Table 3 Cytokine secretion of CD4+CD25-CD69+ T cells before and after stimulation in vitro
Cytokine Stimulation PMA & ionomycin Group A (%) P value Group B (%) P value
IL-2 Before 6.4 (1.4-13.0) 0.347 6.3 (4.3-9.2) 0.917
After 9.3 (1.8-18.4) 6.0 (4.0-10.9)
IL-10 Before 1.5 (0–7.8) 1.000 4.1 (0.3-12.0) 0.754
After 3.2 (0–7.8) 4.8 (1.9-14.2)
TGFβ Before 3.7 (3.2-13.6) 0.117 7.9 (5.7-14.2) 0.602
After 6.5 (5.3-23.5) 6.9 (5.0-20.7)
Data represent the median% (range) of specific cytokine-secreted CD4+CD25-CD69+ T cells.
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of these cytokines were unaffected by PMA and iono-
mycin stimulation (Table 3). Similar to the results of
the unstimulated bone marrow samples, no clear dif-
ferences in cytokine secretion could be observed between
the patients in group A and group B after stimulation
(P > 0.05, Figure 4c).
Discussion
Among the main recognized subsets of CD4+ T cells in-
volved in negative regulation of the immune response,
most studies have focused on the regulatory function of
CD4+CD25 + Foxp3+ Tregs [20]. In addition to these
well-characterized CD4+CD25+ Tregs, CD4+CD25- T
cells have also been shown to display inhibitory immune
function in some animal models [21-23]. This T cell sub-
set was shown to mediate immune tolerance by attenu-
ating the autoimmune response via both cell-cell contact
mechanisms and the regulation of soluble factor ex-
pression (IL-10 and IFN-γ) [24]. These reports pro-
vided new insight into the mechanisms of tolerance to
allografted transplant. However, CD4+CD25-CD69+ T
cells, which were the subject of our study, not only
possessed a unique immunophenotype but also func-
tioned independently of cytokine secretion. Previous
studies have demonstrated the immunosuppressive
role of CD4+CD25- Tregs in solid tumor models [14,15],
but to our knowledge, no study has focused on the func-
tional roles of this newly identified T cell subset in theTable 4 The incidence of MRD + or relapse comparison betwe
+CD25-CD69+ T cells group at different time point after allo-







The percentage less than 7% was defined as low level group, otherwise was definedevelopment of hematological malignant disease as well as
immunoregulation after allo-HSCT. Here, we investigated
the functional roles of this subset of T cells in patients
with hematological malignancy after allo-HSCT. Thus,
this is the first study to explore the relationship be-
tween CD4+CD25-CD69+ T cells and the progression
of hematological tumors post-transplantation. Our re-
sults indicate this relationship to be an extension of
the immunoregulatory role of these newly identified
Tregs beyond their role in solid tumors.
It remains controversial which source of CD4+CD25-
CD69+ T cells should be selected as the target for tumor
immunity. According to the pathogenesis of acute
GVHD, it is likely the CD4+CD25-CD69+ T cells in the
peripheral blood that display a significant inhibitory ef-
fect during the course of GVHD. Regarding antitumor
immunity, previous studies have been performed in
tumor-bearing mouse models and patients with HCC
(liver-infiltrating lymphocytes), and it is known that
tumor cells can recruit and enrich Tregs to suppress an-
titumor activity [8,10]. Because hematological malignant
cells are derived from and primarily localize in the bone
marrow, we selected CD4+CD25-CD69+ T cells from
the bone marrow as the focus of our study. Indeed, we
observed a correlation between leukemia relapse and the
frequency of this new type of Treg. Additionally, these T
cells were also positively correlated to tumor burden
prior to any intervention after transplant. We then
sought to examine whether CD4+CD25-CD69+ T cellsen high CD4+CD25-CD69+ T cells group and low CD4
HSCT







d as high level group.
Figure 3 The dynamic change of frequency of CD4+CD25-CD69+ T cells in the representative patients of different groups (healthy
donor, n = 3; patients with MRD + n = 3; relapsed patients, n = 3). FCM + represents detectable LAIP. DLI, donor lymphocyte infusion.
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a tumor induced the increase in this subset of T cells,
which led us to the following question: what is the bio-
logical role of CD4+CD25-CD69+ T cells during allo-
HSCT?
Our preliminary data demonstrated that the frequen-
cies of these non-traditional Tregs were relatively high
compared to those of normal control subjects at each
time point post-transplantation except at +30 d. This
finding indicated that these CD4+CD25-CD69+ T cells
could be reconstituted quickly and even expanded after
transplantation. At the early stages after transplant, the
low frequency of CD4+CD25-CD69+ T cells may be due
to incomplete T cell reconstitution. During the second
month, the frequency of these T cells continued to in-
crease and was maintained at a higher level compared to
the normal control group. A similar phenomenon has
also been reported for other immunoregulatory cells
during HSCT. For example, myeloid-derived suppressor
cells (MDSCs), which recently have been shown to pos-
sess immunosuppressive function, expanded after HSCT
both in pre-clinical mouse models and patients with suc-
cessful transplants [25,26]. In vitro functional experi-
ments had further demonstrated the immunoregulatory
role of CD4+CD25-CD69+ T cells in a mouse model[14]. Thus, we speculated that this subset might contri-
bute to the maintenance of immune tolerance after
transplantation. Our previous data also identified a nega-
tive correlation between the frequency of this subset in
the peripheral blood and the incidence of aGVHD; in
particular, the lower frequency of this subset of T cells
led to more severe aGVHD [16]. To a large extent, this
result indicated that CD4+CD25-CD69+ T cells may
exert important immunoregulatory functions after trans-
plantation. In this study, we provided the clinical evi-
dence to support such an immunosuppressive effect of
CD4+CD25-CD69+ T cells during HSCT. The frequency
of this subset of T cells in the bone marrow was signifi-
cantly increased in relapsed patients, whereas in patients
with a lower tumor load (MRD+), a relatively lower
proportion of these T cells was observed. However, the
percentage of these T cells from patients who either
relapsed or had a positive MRD was higher compared to
those of normal control subjects and patients with no
relapse indication at other time points, with the excep-
tion of +30 d. Furthermore, the number of CD4+CD25-
CD69+ T cells declined rapidly after intervention.
Together, these data indicated that the immunosuppres-
sive effect of this subset of T cells likely contributed to
leukemia relapse after transplantation. However, as a
Figure 4 CD4+CD25-CD69+ T cells might not display immune
regulatory function via cytokine secretion. (a). The frequency of
CD4+CD25-CD69+ T cells in group B was significantly higher than
those in group A and healthy donors. (b). No significant difference
of cytokine (IL-2, IL-10 and TGF-β) level was seen among donors and
patients of group A & B before PMA and ionomycin stimulation.
(c). There was no obvious difference of cytokine secretion between
group A and group B after PMA and ionomycin stimulation.
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directly reflect the load of the malignancy; instead, these
cells are more indicative of the immune status of the
transplant recipient. Consistent with this theory, distinct
clinical outcomes for these patients were obtained des-
pite the significant decrease in the frequency of MRD +
or relapsed patients after intervention therapy. For those
patients who did not achieve complete remission, it was
hypothesized that their leukemia cells possessed a
greater likelihood of malignant behavior.Although the frequency of CD4+CD25-CD69+ T cells
could not accurately predict the forthcoming relapse at
each time point (with the exception of +60 d, +90 d and
+270 d), it appeared that this subset of CD4+ Tcells was in-
creased prior to the presence of either MRD+ or leukemia
relapse, according to this case study. The median time for
patients undergoing MRD+ or leukemia relapse was +90 d,
which may explain why a significant group difference at
+60 d after transplant was observed regardless of the
perspective. These results confirmed that CD4+CD25-
CD69+ T cells are negative immunomodulatory cells.
When the frequency of these non-traditional Tregs reaches
an excessive level, patients may develop an excessive form
of immune tolerance and suffer from an impending relapse.
As a result, due to this disruption of the immune balance,
the tumor may have a chance to escape immunological sur-
veillance. Therefore, the frequency of CD4+CD25-CD69+
T cells could represent a suitable parameter to predict the
incidence of leukemia relapse after transplantation.
There are 3 possibilities that could explain the sub-
optimal concordance between the frequency of CD4
+CD25-CD69+ T cells and leukemia relapse. First,
because 14 patients had either relapsed or developed
MRD + at various time points post-transplantation, the
accuracy of relapse prediction at certain time points
could have been impaired. Second, the interval of sample
collection may have affected the accuracy of predicting
relapse, and the interval between sample collection and
relapse could have also interfered with the predictive ef-
ficiency. Third, the bone marrow is a hematopoietic
organ where many types of hematopoietic cells localize,
so there exists the possibility that a small number of ac-
tivated T cells also expressing CD69 are present at this
location. Although the CD4+CD25-CD69+ T cells we
detected also highly express CD122, there may be other
unknown molecular markers that could discriminate this
new regulatory T cell from classically activated T cells.
Finally, to investigate whether the CD4+CD25-CD69+ T
cells in the bone marrow were the same subset of T cells
that had been examined in previous studies [14,15], we
measured the cytokine secretion of these T cells. Consistent
with previous reports, this subset of T cell did not respond
to PMA/ionomycin stimulation. This finding indicated that
despite the difference in the ratio of this non-traditional
Treg in relapsed and non-relapsed patients, the cells se-
creted comparable levels of IL-2, IL-10 and TGF-β. This
finding also suggested that these novel Tregs might exert
their immunosuppressive function independent of cytokine
secretion and through other means such as cell-cell
contact.
Conclusions
In summary, this study presents the first clinical evidence
for the positive correlation between non-traditional
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http://www.translational-medicine.com/content/12/1/187CD4+CD25-CD69+ Tregs and leukemia relapse after allo-
HSCT, although further study is necessary to confirm our
findings. Moreover, we demonstrated the immunosuppres-
sive role of this subset of T cell both in the peripheral
blood and bone marrow towards GVHD and GVL post-
transplantation, respectively. However, the mechanism
underlying their immunosuppressive function remains un-
clear. The precise role of CD4+CD25-CD69+ T cells in
leukemia relapse also requires further exploration and may
lead to the discovery of new methods of adoptive
immunotherapy.
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